Protagonist Therapeutics Inc Revenue Growth Rates (PTGX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Protagonist Therapeutics inc   (NASDAQ: PTGX)
 

PTGX's Revenue Growth by Quarter and Year

Protagonist Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PTGX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 213.48
1st Quarter March 56.37
FY 269.84

PTGXs Annual Revenue
Protagonist Therapeutics Inc 's Revenue in the fiscal year 2025 $ 46.02 millions
Protagonist Therapeutics Inc 's Revenue in the fiscal year 2024 $ 434.43 millions
Protagonist Therapeutics Inc 's Revenue in the fiscal year 2023 $ 60.00 millions
Protagonist Therapeutics Inc 's Revenue in the fiscal year 2022 $ 26.58 millions
Protagonist Therapeutics Inc 's Revenue in the fiscal year 2021 $ 27.36 millions




PTGX Revenue second quarter 2026 Y/Y Growth Comment
Protagonist Therapeutics inc achieved in the second quarter 2026, above Company average Revenue surge of 3746.4% year on year, to $ 213.48 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Revenue growth. While Protagonist Therapeutics Inc ' s Revenue doubling of 3746.4% ranks overall at the positon no. 24 in the second quarter 2026.


PTGX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -95.64 % 184.4 % -
3rd Quarter September - 0.64 % - -
2nd Quarter June 3746.4 % 33.09 % - -
1st Quarter March 99.05 % -88.89 % - -
FY   - -89.41 % 624.07 % -

Financial Statements
Protagonist Therapeutics Inc 's second quarter 2026 Revenue $ 213.48 millions PTGX's Income Statement
Protagonist Therapeutics Inc 's second quarter 2025 Revenue $ 5.55 millions Quarterly PTGX's Income Statement


PTGX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 57.96 % 3546.15 % -
3rd Quarter September - -15.14 % 12.23 % -
2nd Quarter June 278.7 % -80.4 % -98.36 % -
1st Quarter March 657.66 % -83.4 % 324.92 % -
FY (Year on Year)   - -89.41 % 624.07 % -


Back to PTGX Growth rate Comparisons >> Back to PTGX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #6
Healthcare Sector #10
Overall #24

Revenue Y/Y Growth Statistics
High Average Low
3749.17 % 161.14 % -100 %
 
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #6
Healthcare Sector #10
Overall #24
Revenue Y/Y Growth Statistics
High Average Low
3749.17 % 161.14 % -100 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Protagonist Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
3550.01 % 175.39 % -100 %
(Dec 31 2024)  


PTGX's II. Quarter Q/Q Revenue Comment
Protagonist Therapeutics inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 278.7%, to $ 213.48 millions, from $56.37 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Protagonist Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 71.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #28
Overall #71
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #28
Overall #71
Revenue Q/Q Growth Statistics
High Average Low
3550.01 % 175.39 % -100 %
(Dec 31 2024)  


PTGX's II. Quarter Q/Q Revenue Comment
Protagonist Therapeutics inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 278.7%, to $ 213.48 millions, from $56.37 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Protagonist Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 71.


Protagonist Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 281.99 $ 74.06 $ 46.02 $ 209.22 $ 209.18
Y / Y Revenue Growth (TTM) 34.81 % -64.36 % -89.41 % -35.39 % -
Year on Year Revenue Growth Overall Ranking # 3714 # 4431 # 3662 # #
Seqeuential Revenue Change (TTM) 280.75 % 60.95 % -78.01 % 0.02 % 0.66 %
Seq. Revenue Growth (TTM) Overall Ranking # 3714 # 4431 # 3662 # #


Cumulative Revenue growth Comment
Although Protagonist Therapeutics Inc 's Annual Revenue growth year on year were below company's average 121.5% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 34.81% year on year, from -64.36% in Mar 31 2026.

In the Healthcare sector 478 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3714, from total ranking in previous quarter at 4431.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 158
Healthcare Sector # 479
Overall # 3561

Revenue TTM Y/Y Growth Statistics
High Average Low
1393.53 %
 121.5 %
-100.34 %
(Mar 31 2021)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 371
S&P 500 # 2573
Cumulative Revenue growth Comment
Although Protagonist Therapeutics Inc 's Annual Revenue growth year on year were below company's average 121.5% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 34.81% year on year, from -64.36% in Mar 31 2026.

In the Healthcare sector 478 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3714, from total ranking in previous quarter at 4431.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 158
Healthcare Sector # 479
Overall # 3561

Revenue TTM Y/Y Growth Statistics
High Average Low
1393.53 %
121.5 %
-100.34 %
(Mar 31 2021)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 371
S&P 500 # 2573




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PTGX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Nakamoto Inc 6,129.94%$ 6,129.943 millions
Connect Biopharma Holdings Limited5,666.67%$ 5,666.667 millions
Hcw Biologics Inc 3,828.21%$ 3,828.214 millions
Protagonist Therapeutics inc 3,749.17%$ 3,749.171 millions
Aligos Therapeutics Inc 2,778.55%$ 2,778.549 millions
Crinetics Pharmaceuticals Inc 2,336.28%$ 2,336.275 millions
Tao Synergies Inc 2,136.90%$ 2,136.901 millions


About Protagonist Therapeutics Inc Revenue Growth Rates (PTGX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Protagonist Therapeutics Inc (CIK 1377121).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-091123
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Protagonist Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.